To honour the legacy and memory of Myeloma Canada’s co-founder, the Aldo Del Col Research Grant funds patient-prioritized Canadian research projects that help address the knowledge gaps in the diagnosis and treatment of myeloma and/or related plasma cell disorders that were identified through the Myeloma Priority Setting Partnership (PSP).
The Myeloma PSP is a collaborative project between the Horizon Health Network, the Maritime SPOR SUPPORT UNIT (MSSU), and Myeloma Canada, and adhered to established PSP practices set by the James Lind Alliance. Click here to read the published correspondence, “The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership”.
Based on the number and quality of applications, grants totaling at least CDN $350,000 are expected to be awarded in 2024. The minimum award is CDN $50,000 and the maximum award is CDN $150,000. The Independent Research Review Committee (IRRC) will endeavour to award at least 1 grant in each of the following categories:
- Accelerate the development of academic cellular therapies
- Lab/bench projects (including but not limited to the development of novel therapeutics)
- Quality of life, database or real-world evidence that can help:
- accelerate access to treatments;
- inform best practices and standards for treatment;
- highlight the variability/disparities in access to treatment and best/standard practice patterns;
- increase the speed of incorporating new evidence into government policy and clinical practice;
- fill the evidence gaps in myeloma care within healthcare systems to improve access to and delivery of care for patients.
- Clinical trial research components (e.g., quality of life or health economic analyses) that can help:
- increase access to new treatments and drug combinations;
- change clinical practice;
- influence reimbursement decisions;
- ensure treatment access to a wide geographic/demographic representation of patients.
Applications will be accepted from March 15 – May 31, 2024. Funding decisions will be communicated to applicants in October 2024, or earlier. The principal applicant must be a researcher at any career stage, and be affiliated with a Canadian university, hospital, cancer centre, or research institute.
Indirect costs of research (e.g., institutional overhead, pooled costs, G&A, M&A, utilities, maintenance) are not permitted.
2024 Aldo Del Col Research Grant
To honour the legacy and memory of Myeloma Canada’s co-founder, the Aldo Del Col Research Grant funds patient-prioritized Canadian research projects that help address the knowledge gaps in the diagnosis and treatment of myeloma and/or related plasma cell disorders that were identified through the Myeloma Priority Setting Partnership (PSP).
The Myeloma PSP is a collaborative project between the Horizon Health Network, the Maritime SPOR SUPPORT UNIT (MSSU), and Myeloma Canada, and adhered to established PSP practices set by the James Lind Alliance. Click here to read the published correspondence, “The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership”.
Based on the number and quality of applications, grants totaling at least CDN $350,000 are expected to be awarded in 2024. The minimum award is CDN $50,000 and the maximum award is CDN $150,000. The Independent Research Review Committee (IRRC) will endeavour to award at least 1 grant in each of the following categories:
- Accelerate the development of academic cellular therapies
- Lab/bench projects (including but not limited to the development of novel therapeutics)
- Quality of life, database or real-world evidence that can help:
- accelerate access to treatments;
- inform best practices and standards for treatment;
- highlight the variability/disparities in access to treatment and best/standard practice patterns;
- increase the speed of incorporating new evidence into government policy and clinical practice;
- fill the evidence gaps in myeloma care within healthcare systems to improve access to and delivery of care for patients.
- Clinical trial research components (e.g., quality of life or health economic analyses) that can help:
- increase access to new treatments and drug combinations;
- change clinical practice;
- influence reimbursement decisions;
- ensure treatment access to a wide geographic/demographic representation of patients.
Applications will be accepted from March 15 – May 31, 2024. Funding decisions will be communicated to applicants in October 2024, or earlier. The principal applicant must be a researcher at any career stage, and be affiliated with a Canadian university, hospital, cancer centre, or research institute.
Indirect costs of research (e.g., institutional overhead, pooled costs, G&A, M&A, utilities, maintenance) are not permitted.